Report Thumbnail
Product Code LP0913411473RN1
Published Date 2023/3/9
English85 PagesGlobal

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913411473RN1◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/3/9
English 85 PagesGlobal

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Cystic Fibrosis, also known as mucoviscoidosis, is an inherited genetic disorder that affects the secretory glands, including mucus and sweat glands. It mainly affects the lungs and digestive system. An individual suffering from cystic fibrosis show characteristic symptoms, such as, secretion of thick and sticky mucus. The disease develops over a period of time in the lungs and blocks the tubes that carry air in and out. Increased secretion of thick mucus accelerates the growth of bacteria and hence, gives rise to serious lung infections. Some of the major symptoms of cystic fibrosis include persistent cough, constant lung infection, salty tasting skin, problem in breathing, bulky stools, difficulty in bowel movements, poor growth and poor weight gain. Some of the tests available for cystic fibrosis are newborn screening, sweat test, chest x-ray, lung function tests, and genetic testing. Cystic fibrosis can be divided into three segments, namely, cystic fibrosis mutations, curable type of cystic fibrosis, and rare type of cystic fibrosis. Some of the treatment methods for cystic fibrosis are chest physical therapy (CPT), exercise, consumption of antibiotics, lung transplant and postural drainage.
LPI (LP Information)' newest research report, the “Cystic Fibrosis (Mucoviscoidosis) Testing Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis (Mucoviscoidosis) Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis (Mucoviscoidosis) Testing sales for 2023 through 2029. With Cystic Fibrosis (Mucoviscoidosis) Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis (Mucoviscoidosis) Testing industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis (Mucoviscoidosis) Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis (Mucoviscoidosis) Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cystic Fibrosis (Mucoviscoidosis) Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis (Mucoviscoidosis) Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis (Mucoviscoidosis) Testing.
The global Cystic Fibrosis (Mucoviscoidosis) Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
Major driving factors for the growth of the cystic fibrosis market are increasing number of patients suffering from cystic fibrosis, rising need and demand for sophisticated testing tools, and increased government funding for the development of genetic testing. Moreover, every company wants to grow and develop by using pharmacogenomic diagnostic tools, so that they have an enviable position in the existing market. Rapid adoption of potentially advanced tests to diagnose cystic fibrosis and increasing awareness and affordability of the people across geographies will continually provide growth towards this market. On the other hand, factors like huge amount of capital involved and few adverse effects like pulmonary exacerbations and weight gain would most likely impede the growth of this market.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis (Mucoviscoidosis) Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Chest Physical Therapy (CPT)
Consumption Of Antibiotics
Lung Transplant And Postural Drainage
Segmentation by application
Hospitals
Ambulatory Surgical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticals
Abbott
Pfizer
NovaBiotics
Cystic Fibrosis Foundation
Galapagos

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Size 2018-2029
      • 2.1.2 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size CAGR by Region 2018 VS 2022 VS 2029
    • 2.2 Cystic Fibrosis (Mucoviscoidosis) Testing Segment by Type
      • 2.2.1 Chest Physical Therapy (CPT)
      • 2.2.2 Consumption Of Antibiotics
      • 2.2.3 Lung Transplant And Postural Drainage
    • 2.3 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Type
      • 2.3.1 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size CAGR by Type (2018 VS 2022 VS 2029)
      • 2.3.2 Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Market Share by Type (2018-2023)
    • 2.4 Cystic Fibrosis (Mucoviscoidosis) Testing Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Ambulatory Surgical Centers
      • 2.4.3 Others
    • 2.5 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Application
      • 2.5.1 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size CAGR by Application (2018 VS 2022 VS 2029)
      • 2.5.2 Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Market Share by Application (2018-2023)
  • 3 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Player

    • 3.1 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Market Share by Players
      • 3.1.1 Global Cystic Fibrosis (Mucoviscoidosis) Testing Revenue by Players (2018-2023)
      • 3.1.2 Global Cystic Fibrosis (Mucoviscoidosis) Testing Revenue Market Share by Players (2018-2023)
    • 3.2 Global Cystic Fibrosis (Mucoviscoidosis) Testing Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Cystic Fibrosis (Mucoviscoidosis) Testing by Regions

    • 4.1 Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Regions (2018-2023)
    • 4.2 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Growth (2018-2023)
    • 4.3 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Growth (2018-2023)
    • 4.4 Europe Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Growth (2018-2023)
    • 4.5 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing Market Size Growth (2018-2023)
  • 5 Americas

    • 5.1 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Country (2018-2023)
    • 5.2 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Type (2018-2023)
    • 5.3 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Application (2018-2023)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Region (2018-2023)
    • 6.2 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Type (2018-2023)
    • 6.3 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Application (2018-2023)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Cystic Fibrosis (Mucoviscoidosis) Testing by Country (2018-2023)
    • 7.2 Europe Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Type (2018-2023)
    • 7.3 Europe Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Application (2018-2023)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing by Region (2018-2023)
    • 8.2 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Type (2018-2023)
    • 8.3 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing Market Size by Application (2018-2023)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast

    • 10.1 Global Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Regions (2024-2029)
      • 10.1.1 Global Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Regions (2024-2029)
      • 10.1.2 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Forecast
      • 10.1.3 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Forecast
      • 10.1.4 Europe Cystic Fibrosis (Mucoviscoidosis) Testing Forecast
      • 10.1.5 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing Forecast
    • 10.2 Americas Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Country (2024-2029)
      • 10.2.1 United States Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.2.2 Canada Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.2.3 Mexico Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.2.4 Brazil Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
    • 10.3 APAC Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Region (2024-2029)
      • 10.3.1 China Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.3.2 Japan Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.3.3 Korea Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.3.4 Southeast Asia Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.3.5 India Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.3.6 Australia Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
    • 10.4 Europe Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Country (2024-2029)
      • 10.4.1 Germany Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.4.2 France Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.4.3 UK Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.4.4 Italy Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.4.5 Russia Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
    • 10.5 Middle East & Africa Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Region (2024-2029)
      • 10.5.1 Egypt Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.5.2 South Africa Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.5.3 Israel Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.5.4 Turkey Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
      • 10.5.5 GCC Countries Cystic Fibrosis (Mucoviscoidosis) Testing Market Forecast
    • 10.6 Global Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Type (2024-2029)
    • 10.7 Global Cystic Fibrosis (Mucoviscoidosis) Testing Forecast by Application (2024-2029)
  • 11 Key Players Analysis

    • 11.1 Vertex Pharmaceuticals
      • 11.1.1 Vertex Pharmaceuticals Company Information
      • 11.1.2 Vertex Pharmaceuticals Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.1.3 Vertex Pharmaceuticals Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.1.4 Vertex Pharmaceuticals Main Business Overview
      • 11.1.5 Vertex Pharmaceuticals Latest Developments
    • 11.2 Abbott
      • 11.2.1 Abbott Company Information
      • 11.2.2 Abbott Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.2.3 Abbott Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.2.4 Abbott Main Business Overview
      • 11.2.5 Abbott Latest Developments
    • 11.3 Pfizer
      • 11.3.1 Pfizer Company Information
      • 11.3.2 Pfizer Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.3.3 Pfizer Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.3.4 Pfizer Main Business Overview
      • 11.3.5 Pfizer Latest Developments
    • 11.4 NovaBiotics
      • 11.4.1 NovaBiotics Company Information
      • 11.4.2 NovaBiotics Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.4.3 NovaBiotics Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.4.4 NovaBiotics Main Business Overview
      • 11.4.5 NovaBiotics Latest Developments
    • 11.5 Cystic Fibrosis Foundation
      • 11.5.1 Cystic Fibrosis Foundation Company Information
      • 11.5.2 Cystic Fibrosis Foundation Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.5.3 Cystic Fibrosis Foundation Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.5.4 Cystic Fibrosis Foundation Main Business Overview
      • 11.5.5 Cystic Fibrosis Foundation Latest Developments
    • 11.6 Galapagos
      • 11.6.1 Galapagos Company Information
      • 11.6.2 Galapagos Cystic Fibrosis (Mucoviscoidosis) Testing Product Offered
      • 11.6.3 Galapagos Cystic Fibrosis (Mucoviscoidosis) Testing Revenue, Gross Margin and Market Share (2018-2023)
      • 11.6.4 Galapagos Main Business Overview
      • 11.6.5 Galapagos Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Growth (Status and Outlook) 2023-2029 | Pharmaceutical_LifeSciense Market Research Report - ShareFair Markets